Semax vs ARA-290
Both Semax and ARA-290 are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →Side-by-Side
| Attribute | Semax | ARA-290 |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy |
| Typical Dose | 200–600 mcg intranasal, morning | Trial range: 1–4 mg subcutaneous daily |
| Clinics Indexed | 89 | 9 |
| Categories | cognitive, neuroprotection | anti-inflammatory, neuroprotection |
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.